Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device

NCT02600364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-11-20

No results posted yet for this study

Summary

The purpose of this study is to assess safety and effectiveness of the p64 Flow Modulation Device.

Conditions

  • Intracranial Aneurysm

Sponsors & Collaborators

  • Phenox GmbH

    lead INDUSTRY

Principal Investigators

  • Alain Bonafé, Prof. Dr. · Hôpital Gui de Chauliac (CHU de Montpellier), Montpellier, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Argentina
  • Belgium
  • Bulgaria
  • France
  • Germany
  • Italy
  • Poland
  • Romania
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600364 on ClinicalTrials.gov